New approaches to the treatment of Age-Related Macular Degeneration (AMD). (August 2022)

• Record Type: Journal Article
• Authors: Csaky, Karl; Curcio, Christine A.; Mullins, Robert F.; Rosenfeld, Philip J.; Fujimoto, James; Rohrer, Bärbel; Ribero, Ramiro; Malek, Goldis; Waheed, Nadia; Guymer, Robyn; Hageman, Gregory S.; Chen, Hao; Csete, Marie
• Is Part Of: Experimental eye research. Volume 221(2022)
• Publication Date: 2022-08
• Subjects: Bruch's membrane -- Choriocapillaris -- Choroid -- Complement inhibition -- HTRA1 gene -- Lipid dysregulation -- Membrane attack complex -- Optical coherence tomography angiography; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2022.109134
• Languages: English
• ISSNs: 0014-4835

Abstract

Highlights: Choroid and choriocapillaris are potential important targets of therapy early in AMD. Macular vasculature pathology, like choriocapillaris flow deficits, can be measured using OCT-A. Subretinal drusenoid deposits result from biogenesis pathways involved in lipid homeostasis. How to target (over- or under-express) the HtrA1 gene associated with AMD is controversial. Optimal gene therapies for AMD depend on retinal delivery site and specificity to retinal cell.